Rogers Corp. Exceeds Q4 Guidance with Strong Adjusted EPS, Projects Q1 Growth
Summary
Rogers Corporation reported strong fourth-quarter 2025 results, exceeding guidance with significant year-over-year growth in adjusted earnings per share and sales, and provided positive first-quarter 2026 guidance.
Key Events
-
Strong Q4 2025 Adjusted EPS
Adjusted earnings per diluted share for Q4 2025 were $0.89, a significant increase from $0.46 in Q4 2024, exceeding the high-end of guidance.
-
Q4 2025 Net Sales Growth
Net sales for Q4 2025 reached $201.5 million, representing a 4.8% increase compared to the prior year quarter.
-
Full Year GAAP Loss Driven by Restructuring
The company reported a full-year 2025 GAAP net loss of $(61.8) million, primarily due to $97.1 million in restructuring and impairment charges.
-
Positive Q1 2026 Guidance
Management projects 5% sales growth, a 160 basis point improvement in gross margin, and a 530 basis point increase in adjusted EBITDA margin for Q1 2026 compared to Q1 2025.
Analysis
Rogers Corporation's fourth-quarter 2025 performance indicates a positive operational turnaround, with adjusted earnings per share nearly doubling year-over-year and net sales increasing. While the full-year GAAP results show a loss, this is primarily attributable to substantial restructuring and impairment charges, which are non-recurring. The company's guidance for the first quarter of 2026 projects continued sales growth and significant margin expansion, suggesting a sustained positive trajectory. This report highlights the benefits of recent cost improvement initiatives and positions the company for improved results in the coming year, potentially counteracting recent negative sentiment from activist investor share sales on January 24, 2026.
At the time of this filing, ROG was trading at $105.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $51.43 to $112.81. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.